You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

FC(PO)+R

Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Regimen Category: Evidence-informed
Drugs Used:
riTUXimab,
fludarabine,
cyclophosphamide,
riTUXimab (subcut)
Show More Show more tags
, Show Less Show fewer tags

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Regimen Monograph

Aug 2020
Table of Contents

Patient Info Sheet

Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.

You might also be interested in

ALEM; ALEM(IV)

DASA

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration